Unlock instant, AI-driven research and patent intelligence for your innovation.

Water-soluble benzoazepine compound and its pharmaceutical composition

a benzoazepine compound and pharmaceutical technology, applied in the field of new drugs, can solve the problems of poor absorption by the intestinal canal, limited dosage form and administration route, etc., and achieve excellent water solubility, excellent absorption, excellent water solubility

Inactive Publication Date: 2010-01-07
OTSUKA PHARM CO LTD
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0127]Compound (1) of the present invention or a salt thereof has remarkably excellent water solubility, excellent absorbability, etc.
[0128]Compound (1b) in particular or a salt thereof has remarkably excellent water solubility, excellent absorbability, etc.
[0129]When administered into the human body, compound (1) of the present invention or a salt thereof, compound (1b) or a salt thereof in particular, enables the easy generation of the active ingredient tolvaptan.
[0130]Further, compound (1) of the present invention or a salt thereof can be easily crystallized and is excellent in operability. In addition, compound (1) of the present invention or a salt thereof has excellent chemical stability.
[0131]Compound (1a) of the present invention can be suitably used as a starting material for producing compound (1b).
[0132]Use of compound (1) of the present invention or a salt thereof enables compositions to be provided in various forms that express drug efficacy equal to tolvaptan, which is an effective drug.

Problems solved by technology

However, because of its low water solubility, tolvaptan has problems in that it is poorly absorbed by the intestinal canal, its dosage form and administration route are limited, etc.
Although attempts have been made to solve these problems so that, for example, tolvaptan can be administered in the form of an amorphous solid preparation composition (Japanese Unexamined Patent Publication No. 1999-21241), in the application of tolvaptan, its dosage form and administration route still remain limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Water-soluble benzoazepine compound and its pharmaceutical composition
  • Water-soluble benzoazepine compound and its pharmaceutical composition
  • Water-soluble benzoazepine compound and its pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0136]

[0137]A 1.0 g quantity of tolvaptan (compound (2)) and 460 mg of 1H-tetrazole were dissolved in 30 ml of methylene chloride, and 1.2 g of dibenzyl diisopropylphosphoramidite was added dropwise to this solution at room temperature with stirring. The mixture was then stirred for 2 hours at the same temperature.

[0138]The obtained reaction mixture was cooled to −40° C., and 6 ml of methylene chloride solution of 920 mg of metachloroperbenzoic acid was added dropwise thereto. The mixture was then stirred at the same temperature for 30 minutes, and at 0° C. for 30 minutes. The reaction mixture was washed with an aqueous sodium thiosulfate solution and saturated aqueous sodium bicarbonate, and then dried over anhydrous sodium sulfate. The obtained reaction mixture was filtered and concentrated, and the residue was purified by silica gel column chromatography (eluent: n-hexane:ethyl acetate=1:1) to give 1.5 g of amorphous compound (1a-1) (yield 97.2%).

[0139]NMR (DMSO-d6, 100° C.) δ pp...

example 2

[0140]

[0141]A 4.5 g quantity of tolvaptan (compound (2)) and 2.2 g of 1H-tetrazole were dissolved in 120 ml of methylene chloride, and a solution of 4.0 g of di t-butyl diisopropylphosphoramidite dissolved in 10 ml of methylene chloride was added dropwise to this solution with ice-cooling and stirring. The mixture was then stirred at room temperature for 2 hours.

[0142]The obtained reaction mixture was cooled to −40° C., and 20 ml of methylene chloride solution of 4.0 g of metachloro perbenzoic acid was added dropwise thereto. The mixture was then stirred at the same temperature for 30 minutes, and at 0° C. for 40 minutes. The reaction mixture was washed with an aqueous sodium thiosulfate solution and saturated aqueous sodium bicarbonate, and then dried over anhydrous sodium sulfate. The obtained reaction mixture was filtered and concentrated, and the residue was purified by silica gel column chromatography (eluent: hexane:ethyl acetate=1:1) to give 3.0 g of amorphous compound (1a-2)...

example 3

[0144]

[0145]A 5.3 g quantity of compound (1a-1) was dissolved in 100 ml of ethanol, and, using 2 g of 5% palladium-carbon as a catalyst, the solution was subjected to catalytic reduction at room temperature and atmospheric pressure for 10 minutes. The catalyst was removed from the solution by filtration, and the obtained filtrate was concentrated (4.2 g). The obtained residue was crystallized from methanol / water. The crystals were collected by filtration and then dried under reduced pressure (diphosphorus pentoxide) to give 3.5 g of white powdery compound (1b) (yield 88.5%).

[0146]Melting point: 150 to 152° C.

[0147]NMR (DMSO-d6-D2O, 100° C.) δ ppm; 7.50-6.70 (10H, m), 5.50-5.40 (1H, m), 5.00-2.50 (2H, m), 2.37 (6H, s), 2.40-1.50 (4H, m)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention provides a benzoazepine compound represented by following general formula (1):or a salt thereof,wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and can be suitably used for injections.

Description

TECHNICAL FIELD[0001]The present invention relates to a novel benzoazepine compound and its pharmaceutical composition.BACKGROUND OF ART[0002]Tolvaptan represented by the following formula (2) is a known compound, and has been disclosed in, for example, U.S. Pat. No. 5,258,510 specification (Example 1199).[0003]It is known that tolvaptan is useful as a vasopressin antagonist having aquaretic activity (Circulation, 107, pp. 2690-2696 (2003)). However, because of its low water solubility, tolvaptan has problems in that it is poorly absorbed by the intestinal canal, its dosage form and administration route are limited, etc. Although attempts have been made to solve these problems so that, for example, tolvaptan can be administered in the form of an amorphous solid preparation composition (Japanese Unexamined Patent Publication No. 1999-21241), in the application of tolvaptan, its dosage form and administration route still remain limited.DISCLOSURE OF THE INVENTION[0004]The present inve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/675C07F9/553
CPCC07F9/5535Y02P20/55A61P13/12A61P43/00A61P7/00A61P7/02A61P7/10A61P9/00A61P9/02A61P9/08A61P9/12C07F9/553A61K31/675C07F9/5532
Inventor KOMATSU, MAKOTOGOTO, FUMITAKAMENJO, YASUHIROYAMADA, KEIGOMATSUDA, TAKAKUNIKATO, YUSUKE
Owner OTSUKA PHARM CO LTD